# Scilex Holding (stock symbol: SCLX) Logo in transparent PNG format

## Scilex Holding Logo large

### Scilex Holding Logo large Download PNG (57.05 KB)

![Scilex Holding Logo large Download PNG (57.05 KB)](/img/orig/SCLX_BIG-0f37aa09.png)

## Scilex Holding Logo icon format

### Scilex Holding Logo icon format Download PNG (24.73 KB)

![Scilex Holding Logo icon format Download PNG (24.73 KB)](/img/orig/SCLX-efcf4c8b.png)

## Scilex Holding Logo large for dark backgrounds

### Scilex Holding Logo large for dark backgrounds Download PNG (16.11 KB)

![Scilex Holding Logo large for dark backgrounds Download PNG (16.11 KB)](/img/orig/SCLX_BIG.D-916f086b.png)

## Scilex Holding Logo icon format for dark backgrounds

### Scilex Holding Logo icon format for dark backgrounds Download PNG (6.23 KB)

![Scilex Holding Logo icon format for dark backgrounds Download PNG (6.23 KB)](/img/orig/SCLX.D-0b1f4c13.png)

## About Scilex Holding

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.

1. Website domain: scilexholding.com
2. Employees: 85
3. Marketcap: $1.05 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
